{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:28:30Z","timestamp":1786796910159,"version":"build-2736575974"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010289","name":"Princess Margaret Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004622","name":"KWF Dutch Cancer Society","doi-asserted-by":"publisher","award":["NKI 2009-4568"],"award-info":[{"award-number":["NKI 2009-4568"]}],"id":[{"id":"10.13039\/501100004622","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.radonc.2026.111551","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T03:34:03Z","timestamp":1778729643000},"page":"111551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trial"],"prefix":"10.1016","volume":"222","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7736-6789","authenticated-orcid":false,"given":"Monique C.","family":"de Jong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6793-2863","authenticated-orcid":false,"given":"Andrew J.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 S.A.","family":"Belderbos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"van Werkhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferry","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter V.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel M.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eug\u00e8ne M.F.","family":"Damen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Jakob","family":"Sonke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3752-8274","authenticated-orcid":false,"given":"Heike M.U.","family":"Peulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111551_b0005","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111551_b0010","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1200\/JCO.2009.26.2543","article-title":"Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer","volume":"28","author":"Aup\u00e9rin","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0015","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0167-8140(99)00087-0","article-title":"Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART steering committee","volume":"52","author":"Saunders","year":"1999","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0020","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.ijrobp.2006.04.034","article-title":"Final results of a phase I\/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy","volume":"66","author":"Belderbos","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111551_b0025","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ijrobp.2005.02.010","article-title":"High-dose radiation improved local tumor control and overall survival in patients with inoperable\/unresectable non-small-cell lung cancer: long-term results of a radiation dose escalation study","volume":"63","author":"Kong","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111551_b0030","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2001.19.1.127","article-title":"Dose escalation in non \u2013 small-cell lung cancer using three-dimensional conformal radiation therapy\u00a0: update of a phase I trial purpose\u00a0: materials and methods\u00a0: a standard phase I design results\u00a0: at the time of this writing , 104 patients ha","volume":"19","author":"Hayman","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0035","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","author":"Bradley","year":"2019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0040","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1470-2045(14)71207-0","article-title":"Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p","volume":"16","author":"Bradley","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0045","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0050","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijrobp.2004.06.260","article-title":"Toxicity and outcome results of RTOG 9311: a phase I\u2013II dose-escalation study using three-dimensional conformal radiotherapy in patients with inoperable non\u2013small-cell lung carcinoma","volume":"61","author":"Bradley","year":"2005","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0055","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2018.09.019","article-title":"The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)","volume":"131","author":"van Diessen","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0060","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1200\/JCO-24-01386","article-title":"Toxicity within 6 months of heterogeneous fluorodeoxyglucose-guided radiotherapy dose escalation for locally advanced non-small cell lung cancer in the scandinavian randomized phase III NARLAL2 Trial","volume":"43","author":"Schytte","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0065","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1470-2045(18)30896-9","article-title":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","volume":"20","author":"Ball","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102573","article-title":"Stereotactic body radiation therapy in unresectable stage III non-small cell lung cancer: a systematic review","volume":"118","author":"Allignet","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.radonc.2026.111551_b0075","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.3390\/curroncol28050324","article-title":"Feasibility of stereotactic body radiation therapy on unresectable stage III NSCLC with peripheral primary tumor: a prospective study (GFPC 01-14)","volume":"28","author":"Martel-Lafay","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0080","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.radonc.2019.07.015","article-title":"SBRT combined with concurrent chemoradiation in stage III NSCLC: Feasibility study of the phase I Hybrid trial","volume":"142","author":"Peulen","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0085","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.0006-341X.2000.01177.x","article-title":"Sequential designs for phase I clinical trials with late-onset toxicities","volume":"56","author":"Cheung","year":"2000","journal-title":"Biometrics"},{"key":"10.1016\/j.radonc.2026.111551_b0090","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.radonc.2019.07.028","article-title":"Safety and efficacy of reduced dose and margins to involved lymph node metastases in locally advanced NSCLC patients","volume":"143","author":"van Diessen","year":"2020","journal-title":"Radiother Oncol J Eur Soc Ther Radiol Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0095","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.ijrobp.2007.10.059","article-title":"Universal survival curve and single fraction equivalent dose: useful tools in understanding potency of ablative radiotherapy","volume":"70","author":"Park","year":"2008","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000864","article-title":"A generalized linear-quadratic model for radiosurgery, stereotactic body radiation therapy, and high-dose rate brachytherapy","volume":"2","author":"Wang","year":"2010","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.radonc.2026.111551_b0105","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2006.09.005","article-title":"Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973)","volume":"43","author":"Belderbos","year":"2007","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111551_b0110","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.ijrobp.2012.01.088","article-title":"Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass-like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer","volume":"84","author":"Dunlap","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111551_b0115","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0169-5002(94)91859-7","article-title":"Endpoints for multimodal clinical trials in Stage III non-small cell lung cancer (NSCLC): a consensus report","volume":"11","author":"Green","year":"1994","journal-title":"Lung Cancer"},{"key":"10.1016\/j.radonc.2026.111551_b0120","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1200\/JCO.2016.69.1378","article-title":"Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial","volume":"35","author":"Chun","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0125","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.radonc.2018.12.015","article-title":"Modeling radiation pneumonitis of pulmonary stereotactic body radiotherapy: the impact of a local dose\u2013effect relationship for lung perfusion loss","volume":"132","author":"Selvaraj","year":"2019","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0130","doi-asserted-by":"crossref","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","article-title":"Radiation dose-volume effects in the lung","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol \u2022 Biol \u2022 Phys"},{"key":"10.1016\/j.radonc.2026.111551_b0135","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3109\/0284186X.2010.521192","article-title":"Heart irradiation as a risk factor for radiation pneumonitis","volume":"50","author":"Huang","year":"2011","journal-title":"Acta Oncol Stockh Swed"},{"key":"10.1016\/j.radonc.2026.111551_b0140","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non\u2013small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0145","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ijrobp.2024.03.050","article-title":"Stereotactic radiation for ultra-central non-small cell lung cancer: a safety and efficacy trial (SUNSET)","volume":"120","author":"Giuliani","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111551_b0150","doi-asserted-by":"crossref","unstructured":"Salunkhe, R. et al. Dosimetric Outcomes of Stereotactic Body Radiation Therapy to Ultracentral Lung Tumors: Lessons From the SUNSET Trial. Int. J. Radiat. Oncol. https:\/\/doi.org\/10.1016\/j.ijrobp.2025.08.052 (2025) doi:10.1016\/j.ijrobp.2025.08.052.","DOI":"10.1016\/j.ijrobp.2025.08.052"},{"key":"10.1016\/j.radonc.2026.111551_b0155","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.ijrobp.2018.11.036","article-title":"Chest wall toxicity after stereotactic body radiation therapy: a pooled analysis of 57 studies","volume":"103","author":"Ma","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111551_b0160","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.radonc.2017.01.004","article-title":"Dose\u2013effect analysis of radiation induced rib fractures after thoracic SBRT","volume":"123","author":"Stam","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0165","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1097\/JTO.0b013e3182307e74","article-title":"Incidence and risk factors for chest wall toxicity after risk-adapted stereotactic radiotherapy for early-stage lung cancer","volume":"6","author":"Bongers","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0170","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0175","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after chemoradiotherapy in stage III non\u2013small-cell lung cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111551_b0180","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111551_b0185","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ijrobp.2023.10.005","article-title":"Patterns of failure, low-volume relapse, and subsequent ablative management in locally advanced non-small cell lung cancer treated with definitive chemoradiation and consolidation immune checkpoint inhibitors","volume":"118","author":"Friedes","year":"2024","journal-title":"Int J Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0190","doi-asserted-by":"crossref","unstructured":"Vanpouille-box, C. et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. https:\/\/doi.org\/10.1038\/ncomms15618 (2017) doi:10.1038\/ncomms15618.","DOI":"10.1038\/ncomms15618"},{"key":"10.1016\/j.radonc.2026.111551_b0195","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1038\/s43018-025-01018-w","article-title":"Combination of pembrolizumab and radiotherapy induces systemic antitumor immune responses in immunologically cold non-small cell lung cancer","volume":"6","author":"Huang","year":"2025","journal-title":"Nat Cancer"},{"key":"10.1016\/j.radonc.2026.111551_b0200","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1470-2045(24)00573-4","article-title":"Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial","volume":"26","author":"Heinzerling","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111551_b0205","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1016\/j.ijrobp.2024.07.1917","article-title":"NRG LU008: phase III prospective randomized trial of primary lung tumor Stereotactic Body Radiation Therapy (SBRT) followed by concurrent mediastinal chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC)","volume":"120","author":"Simone","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111551_b0210","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0169-5002(99)00113-0","article-title":"The impact of overall treatment time on outcomes in radiation therapy for non-small cell lung cancer","volume":"28","author":"Chen","year":"2000","journal-title":"Lung Cancer Amst Neth"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026003907?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026003907?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:18:34Z","timestamp":1786796314000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026003907"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S0167814026003907"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111551","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous concurrent chemoradiation and SBRT in stage III NSCLC: Safety report of the phase I hybrid trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111551"}}